Maxim Group Maintains Dermata Therapeutics(DRMA.US) With Buy Rating, Announces Target Price $6
Maxim Group Maintains Dermata Therapeutics(DRMA.US) With Buy Rating, Announces Target Price $6
Dermata Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Spruce Biosciences (SPRB), Dermata Therapeutics (DRMA)
Analysts Offer Insights on Healthcare Companies: Star Equity Holdings (STRR), Applied DNA Sciences (APDN) and Dermata Therapeutics (DRMA)
Maxim Adjusts Price Target on Dermata Therapeutics to $4 From $16, Keeps Buy Rating
Maxim Group Sticks to Its Buy Rating for Dermata Therapeutics (DRMA)
Maxim Group Sticks to Its Buy Rating for Dermata Therapeutics (DRMA)
No Data